8.7 C
New York
Thursday, March 28, 2024

BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Courtesy of Benzinga.

NuPathe Inc. (NASDAQ: PATH), today announced that it has granted time-based stock options to Armando Anido, the Company’s newly appointed chief executive officer, pursuant to the NASDAQ inducement grant exception. The inducement grants were approved by the Company’s board of directors and are being made as an inducement material to Mr. Anido’s acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). NuPathe previously announced that Mr. Anido was appointed chief executive officer and a member of the Company’s board of directors effective July 25, 2012.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,450FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x